semaglutide gastroparesis class action in louisiana Woman sues drug makers of Ozempic and Mounjaro over severe gastrointestinal issues semaglutide digestive blockage law office

2024;7:e2423385e2423385

That number is not just large in absolute terms, it is the largest weight-loss signal ever reported in a randomized Phase 3 trial of a GLP-1-class compound, and it arrived with additional secondary findings that reframe what "GLP-1 therapy" could eventually mean: a 75.8% reduction in osteoarthritis pain, a roughly 20% drop in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia in the affected subpopulation

The most frequently observed events included hypertension, palpitations and, within neurological symptoms, seizures and stroke [75]

Patients who continue semaglutide maintain their weight loss and continue to see additional benefits: sustained appetite reduction, improved metabolic markers, and lower cardiovascular risk